For research use only. Not for therapeutic Use.
Erasin is a potent Erlotinib (HY-50896)-resistance antagonizing STAT3 inhibitor with IC50s of 9.7 and 24 μM against STAT3 and STAT1, respectively. Erasin induces cancer cells apoptosis[1].
Erasin inhibits protein-protein interactions mediated by STAT SH2 domains[1].
Erasin (0-80 μM; 24 h) induces apoptosis in MDA-MB-231, HCC-827 and Erlotinib (HY-50896)-resistant HCC-827 cells[1].
| Catalog Number | I026973 |
| Synonyms | N-[(E)-(6-tert-butyl-4-oxochromen-3-yl)methylideneamino]pyridine-3-carboxamide |
| Molecular Formula | C20H19N3O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C20H19N3O3/c1-20(2,3)15-6-7-17-16(9-15)18(24)14(12-26-17)11-22-23-19(25)13-5-4-8-21-10-13/h4-12H,1-3H3,(H,23,25)/b22-11+ |
| InChIKey | JHUVYXUBEMYTNO-SSDVNMTOSA-N |
| SMILES | CC(C)(C)C1=CC2=C(C=C1)OC=C(C2=O)C=NNC(=O)C3=CN=CC=C3 |
| Reference | [1]. Lis C, et al. Development of Erasin: a chromone-based STAT3 inhibitor which induces apoptosis in Erlotinib-resistant lung cancer cells. Sci Rep. 2017 Dec 12;7(1):17390. |
